UPDATE: Deutsche Bank Initiates Coverage on Arrowhead Research on Good Potential

In a report published Wednesday, Deutsche Bank analyst Alethia Young initiated coverage on Arrowhead Research ARWR with a Buy rating and $45.00 price target. In the report, Deutsche Bank noted, “Arrowhead is an early stage platform company that we believe could have the market cap potential of $4-5B as it becomes de-risked. The company's lead target is ARC-520 for Hepatitis B (HBV). Our HBV deep dive suggests ARC-520 could grow the market from $2B to $5B and see $5.2B peak sales WW. Ph2a data in 4Q14, and ph2b data in 2015 provide significant upside & the oppy to de-risk the platform over the next 12-18 mos. We also think HBV & HCV markets have strong parallels.” Arrowhead Research closed on Tuesday at $21.14.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsAlethia YoungDeutsche Bank
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!